WHY IS 3CPM A GREAT INVESTMENT?
WHY IS 3CPM A GREAT INVESTMENT?
Endoscopic therapy for Gastroparesis has been PREVIOUSLY recognized as  unpredictable.
    • The reason for the lack of efficacy of endoscopic therapy has been due to poor patient selection.
    • Today, Electrogastrography is the key to proper sub typing of Gastroparesis and determines the success of endoscopic or other therapy.
    • This provides an unprecedented prestige building and marketing opportunity for the ASC, Endocenter or Hospital to offer the ability to cure or control a disease that was thought to be incurable or uncontrollable.
    • The introduction of electrogastrography is not only cost effective but represents a new and unlimited revenue stream.
AN estimated 40 million Americans  suffer from this disease.
    • 25-28% of the disease sufferers have the EGG defined subtype that has been demonstrated to be cured with endoscopic balloon dilation.
    • 3CPM® GMAT® software successfully detects this subtype and predicts a 93% response to endoscopic pyloric balloon dilation.
    • Other pyloric therapy such as BOTOX injection, G-Poem and pyloroplasty have been found to be effective in this subtype of Gastroparesis
Other subtypes determined by EGG also predict THE out come of surgical therapy
  • Enterra stimulator outcomes improve if quality of ICC’s is assured, and the 3cpm signal correlates with quality and quantities of ICC’s
Personalized Treatment Of Gastroparesis Improves Patient Outcomes
Enhances community and regional reputation, attracting more patients who will require additional services.
Endoscopic therapy for Gastroparesis has been PREVIOUSLY recognized as  unpredictable.
    • The reason for the lack of efficacy of endoscopic therapy has been due to poor patient selection.
    • Today, Electrogastrography is the key to proper sub typing of Gastroparesis and determines the success of endoscopic or other therapy.
    • This provides an unprecedented prestige building and marketing opportunity for the ASC, Endocenter or Hospital to offer the ability to cure or control a disease that was thought to be incurable or uncontrollable.
    • The introduction of electrogastrography is not only cost effective but represents a new and unlimited revenue stream.
AN estimated 40 million Americans  suffer from this disease.
    • 25-28% of the disease sufferers have the EGG defined subtype that has been demonstrated to be cured with endoscopic balloon dilation.
    • 3CPM® GMAT® software successfully detects this subtype and predicts a 93% response to endoscopic pyloric balloon dilation.
    • Other pyloric therapy such as BOTOX injection, G-Poem and pyloroplasty have been found to be effective in this subtype of Gastroparesis
Other subtypes determined by EGG also predict THE out come of surgical therapy
  • Enterra stimulator outcomes improve if quality of ICC’s is assured, and the 3cpm signal correlates with quality and quantities of ICC’s
Personalized Treatment Of Gastroparesis Improves Patient Outcomes
Enhances community and regional reputation, attracting more patients who will require additional services.
Do you want to know how much money you can bring into your endoscopy center using an EGG? Find out in just a few clicks by using our app!